Research
Hormonal
Combinations of GLP-1 RA, GIP, and glucagon RA (retatrutide) have shown weight loss efficacy approaching that of bariatric surgery.
Combination therapies may offer significant weight loss benefits similar to surgical options.
StrongSupportsmedium confidence
Notably, the combinations of GLP-1 RA, GIP and glucagon RA (retatrutide) have shown WL efficacy closing on to that observed in bariatric surgery.
Why this rating
The claim is based on promising data from clinical trials.
Source
Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies
Kaivalya Abburi et al. · Panminerva Medica · 2025
DOI 10.23736/s0031-0808.25.05339-x
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →